SELP and myeloid sarcoma: Molecular MRI targeting at P-selectin is used for the detection of BEC activation, which is promising for clinical translation to monitor or even predict the activity and severity of MS, indicating BBB disruption and BEC activation in the early stage of MS (Gauberti et al., 2018).